drugset / Trial / NCT04121468
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
Phase 1/2
Recruiting
20 enrolled
The Hospital for Sick Children
Multiple Sclerosis Society of Canada · collabOntario Institute for Regenerative Medicine · collabQueen's University · collabStem Cell Network · collabUnity Health Toronto · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.
Timeline
- Start
- 2020-02-24
- Primary completion
- 2027-03
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 1000 mg/m2 | Oral |